A new Citizen Petition filed with FDA on November 17th (PDF) by D.C. law firm Kleinfeld, Kaplan and Becker (KKB) on behalf of an unnamed client, states that it aims to “assure that psychedelic drug products are uniformly subject to the same rigorous medical and scientific approval framework applicable to other classes of drugs.” While it nominally concerns all pending psychedelic NDAs…

Source

Previous articleFrom Approvals to Appointments: Who Pays for Psychedelic Therapy, and How?